Identification of a novel non-functional CYP2D6 allele, CYP2D6*69, in a Caucasian poor metabolizer individual.

作者信息

Gaedigk Andrea, Frank Dorothee, Fuhr Uwe

机构信息

Section of Developmental Pharmacology and Experimental Therapeutics, Children's Mercy Hospital & Clinics, 2401 Gillham Road, Kansas City, MO 64108, USA.

出版信息

Eur J Clin Pharmacol. 2009 Jan;65(1):97-100. doi: 10.1007/s00228-008-0559-6. Epub 2008 Sep 17.

DOI:10.1007/s00228-008-0559-6

PMID:18797858

Abstract

摘要

相似文献

Identification of a novel non-functional CYP2D6 allele, CYP2D6*69, in a Caucasian poor metabolizer individual.

Eur J Clin Pharmacol. 2009 Jan;65(1):97-100. doi: 10.1007/s00228-008-0559-6. Epub 2008 Sep 17.

Genetic polymorphism of CYP2D6 and CYP2C19 metabolism determined by phenotyping Israeli ethnic groups.

Ther Drug Monit. 2000 Oct;22(5):510-6. doi: 10.1097/00007691-200010000-00002.

Assessment of activity levels for CYP2D6*1, CYP2D6*2, and CYP2D6*41 genes by population pharmacokinetics of dextromethorphan.

Clin Pharmacol Ther. 2010 Nov;88(5):643-51. doi: 10.1038/clpt.2010.137. Epub 2010 Sep 29.

A rare insertion of T226 in exon 1 of CYP2D6 causes a frameshift and is associated with the poor metabolizer phenotype: CYP2D6*15.

Pharmacogenetics. 1996 Jun;6(3):269-72. doi: 10.1097/00008571-199606000-00012.

Identification and characterization of CYP2D6*56B, an allele associated with the poor metabolizer phenotype.

Clin Pharmacol Ther. 2007 Jun;81(6):817-20. doi: 10.1038/sj.clpt.6100125. Epub 2007 Mar 28.

CYP2D6 and CYP2C19 activity in a large population of Dutch healthy volunteers: indications for oral contraceptive-related gender differences.

Eur J Clin Pharmacol. 1999 May;55(3):177-84. doi: 10.1007/s002280050615.

The effect of CYP2D6 polymorphisms on dextromethorphan metabolism in Mexican Americans.

J Clin Pharmacol. 2005 Nov;45(11):1230-5. doi: 10.1177/0091270005280755.

Comparison of three CYP2D6 probe substrates and genotype in Ghanaians, Chinese and Caucasians.

Pharmacogenetics. 1998 Aug;8(4):325-33. doi: 10.1097/00008571-199808000-00006.

Characterization of variant alleles of cytochrome CYP2D6 in a Spanish population.

Cell Biochem Funct. 2006 Sep-Oct;24(5):381-5. doi: 10.1002/cbf.1258.

The CYP2D6 activity score: translating genotype information into a qualitative measure of phenotype.

Clin Pharmacol Ther. 2008 Feb;83(2):234-42. doi: 10.1038/sj.clpt.6100406. Epub 2007 Oct 31.

引用本文的文献

The frequencies of CYP2D6 alleles and their impact on clinical outcomes of adjuvant tamoxifen therapy in Syrian breast cancer patients.

BMC Cancer. 2022 Oct 15;22(1):1067. doi: 10.1186/s12885-022-10148-8.

Frequencies of CYP2D6 genetic polymorphisms in Arab populations.

Hum Genomics. 2022 Feb 5;16(1):6. doi: 10.1186/s40246-022-00378-z.

Recommendations for Clinical CYP2D6 Genotyping Allele Selection: A Joint Consensus Recommendation of the Association for Molecular Pathology, College of American Pathologists, Dutch Pharmacogenetics Working Group of the Royal Dutch Pharmacists Association, and the European Society for Pharmacogenomics and Personalized Therapy.

J Mol Diagn. 2021 Sep;23(9):1047-1064. doi: 10.1016/j.jmoldx.2021.05.013. Epub 2021 Jun 10.

Defining screening panel of functional variants of CYP1A1, CYP2C9, CYP2C19, CYP2D6, and CYP3A4 genes in Serbian population.

Int J Legal Med. 2020 Mar;134(2):433-439. doi: 10.1007/s00414-019-02234-7. Epub 2019 Dec 20.

CYP2D6 Haplotype Determination Using Long Range Allele-Specific Amplification: Resolution of a Complex Genotype and a Discordant Genotype Involving the CYP2D6*59 Allele.

J Mol Diagn. 2015 Nov;17(6):740-8. doi: 10.1016/j.jmoldx.2015.06.007. Epub 2015 Sep 1.

Pharmacogenetics in American Indian populations: analysis of CYP2D6, CYP3A4, CYP3A5, and CYP2C9 in the Confederated Salish and Kootenai Tribes.

Pharmacogenet Genomics. 2013 Aug;23(8):403-14. doi: 10.1097/FPC.0b013e3283629ce9.

Intronic polymorphisms of cytochromes P450.

Hum Genomics. 2010 Aug;4(6):402-5. doi: 10.1186/1479-7364-4-6-402.

本文引用的文献

Effect of an antiretroviral regimen containing ritonavir boosted lopinavir on intestinal and hepatic CYP3A, CYP2D6 and P-glycoprotein in HIV-infected patients.

Clin Pharmacol Ther. 2008 Jul;84(1):75-82. doi: 10.1038/sj.clpt.6100452. Epub 2008 Jan 9.

The CYP2D6 activity score: translating genotype information into a qualitative measure of phenotype.

Clin Pharmacol Ther. 2008 Feb;83(2):234-42. doi: 10.1038/sj.clpt.6100406. Epub 2007 Oct 31.

Comparative metabolic capabilities and inhibitory profiles of CYP2D6.1, CYP2D6.10, and CYP2D6.17.

Drug Metab Dispos. 2007 Aug;35(8):1292-300. doi: 10.1124/dmd.107.015354. Epub 2007 Apr 30.

Impaired expression of CYP2D6 in intermediate metabolizers carrying the *41 allele caused by the intronic SNP 2988G>A: evidence for modulation of splicing events.

Pharmacogenet Genomics. 2006 Oct;16(10):755-66. doi: 10.1097/01.fpc.0000230112.96086.e0.

Sequence-based analysis of the CYP2D6*36-CYP2D6*10 tandem-type arrangement, a major CYP2D6*10 haplotype in the Japanese population.

Drug Metab Pharmacokinet. 2006 Jun;21(3):208-16. doi: 10.2133/dmpk.21.208.

Effect of propiverine on cytochrome P450 enzymes: a cocktail interaction study in healthy volunteers.

Drug Metab Dispos. 2005 Dec;33(12):1859-66. doi: 10.1124/dmd.105.005272. Epub 2005 Sep 23.

A novel intronic mutation, 2988G>A, with high predictivity for impaired function of cytochrome P450 2D6 in white subjects.

Clin Pharmacol Ther. 2004 Aug;76(2):128-38. doi: 10.1016/j.clpt.2004.04.009.

Cytochrome P450 2D6: overview and update on pharmacology, genetics, biochemistry.

Naunyn Schmiedebergs Arch Pharmacol. 2004 Jan;369(1):23-37. doi: 10.1007/s00210-003-0832-2. Epub 2003 Nov 15.

The decreased in vivo clearance of CYP2D6 substrates by CYP2D6*10 might be caused not only by the low-expression but also by low affinity of CYP2D6.

Arch Biochem Biophys. 2000 Aug 15;380(2):303-8. doi: 10.1006/abbi.2000.1936.

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型，支持多种主流文档格式。

立即体验